Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Myelodysplastic Syndromes (MDS). Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Myelodysplastic Syndromes (MDS) (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 111 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Definition, Etiology, and Epidemiology

The myelodysplastic syndromes (MDS) are group of clonal hematopoietic stem cell neoplasms characterized by peripheral blood cytopenia (due to ineffective hematopoiesis), dysplasia in one or more myeloid cell lines, and increased risk of developing acute myeloid leukemia.
MDS fall into two main categories: de novo cases with no previous exposure to cytotoxic agents, and secondary cases related to prior chemotherapy or radiation therapy.
The clonal disorders of MDS lead to ineffective hematopoiesis in spite of the hyper-cellular bone marrow. The causes that contribute to the MDS are not well understood, but some may be caused by cytotoxic agents, chemicals, alkylating agents, radiation, or chemotherapeutic drugs. Exposure to environmental agents may have similar effects on the bone marrow stem cells (eg, exposure to benzene, cigarette, agricultural chemicals, or industrial solvents). Some hereditary factors, such as Fanconi anemia, can be associated with increased risk of developing MDS.
The syndromes occur predominantly in adults with median age of 70. MDS are rare in children, and are more predominant in males than females. Many of the features seen in adults MDS are also observed in children MDS. These include morphologic, immunophenotypic, and genetic abnormalities.
Progression to acute myeloid leukemia is the natural course of MDS. The risk of developing AML is higher in certain subtypes of MDS, such as in MDS with excess blasts.